Key regions: France, India, United Kingdom, South Korea, Japan
The Multiple Sclerosis Drugs market in Malta has been developing at a steady pace in recent years.
Customer preferences: Malta's healthcare system is heavily influenced by the British model, and the country has a universal healthcare system. Patients with Multiple Sclerosis (MS) have access to a range of treatments, including disease-modifying therapies (DMTs) and symptomatic treatments. The majority of MS patients in Malta are treated with DMTs, which are designed to slow the progression of the disease and reduce the frequency and severity of relapses.
Trends in the market: The Multiple Sclerosis Drugs market in Malta has been growing steadily in recent years due to several factors. One of the main drivers of growth has been the increasing prevalence of MS in the country. Another factor has been the introduction of new and more effective DMTs, which have helped to improve patient outcomes and reduce the burden of the disease. Additionally, the increasing availability of these drugs has helped to improve patient access and reduce treatment costs.
Local special circumstances: Malta is a small island nation with a population of just over 500,000 people. The country's healthcare system is heavily subsidized by the government, which helps to ensure that patients have access to affordable and high-quality care. Additionally, Malta's membership in the European Union has helped to facilitate the importation of drugs and other medical products from other EU countries, which has helped to improve patient access to these products.
Underlying macroeconomic factors: The Multiple Sclerosis Drugs market in Malta is also influenced by several underlying macroeconomic factors. These include the country's overall economic growth, which can affect the availability of healthcare resources and the affordability of medical treatments. Additionally, changes in government healthcare policies can also have an impact on the market, as can shifts in the global pharmaceutical industry. Overall, however, the Multiple Sclerosis Drugs market in Malta is expected to continue to grow in the coming years, driven by increasing patient demand and the introduction of new and more effective treatments.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
